Statement: Implementation of CETA
Ottawa, September 7, 2017
The following statement can be attributed to Pamela Fralick, President, Innovative Medicines Canada.
“Innovative Medicines Canada (IMC) has supported the Comprehensive and Economic Trade Agreement (CETA) between Canada and the European Union since the beginning of negotiations in 2009. CETA represented an important opportunity for Canada to improve its intellectual property provisions to the level of its major trading partners. Improving our intellectual property regime is one essential component of allowing Canada’s bio-sciences sector to continue to grow and provide high-quality jobs to Canadians, attracting investment in research and development and finding the next generation of medicines.
With the release of the CETA implementation regulations, Canada has made a significant step to provide innovators with some compensation for delays in obtaining marketing approval for pharmaceuticals. However, the regulations have also substantially changed Canada’s patent linkage regulations in a manner not required under CETA, and which we believe will increase the amount of patent litigation in Canada. IMC will continue to work with governments to support the Canadian life sciences environment and to improve access to new medicines in Canada.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information: